Juan Lopez Gomez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Juan Lopez Gomez has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Bárbara Cancho
Service of Nephrology, Badajoz University Hospital, 06006 Badajoz, Spain
3 shared publications - Nicolás Roberto Robles
University of Extremadura
3 shared publications - Alvaro Alvarez Lopez
University of Extremadura
2 shared publications - Jorge Alberto Rodriguez Sabillon
Don Benito-Villanueva Hospital, Nephrology Department, 06400 Don Benito, Spain
2 shared publications - Julian Valladares
Servicio de Nefrologia Hospital Universitario de Badajoz, Universidad de Extremadura Badajoz Spain
2 shared publications - Guadalupe García-Pino
Service of Nephrology, Zafra Hospital, Badajoz, Spain
1 shared publication
Latest Publications
- Open Access
- 23 December 2024
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 39 (2) , e25139
Comparative Prognostic Value of Glomerular Filtration Rate, Serum Cystatin C, Beta‐2‐Microglobulin and Albuminuria for Death and Chronic Kidney Disease Progression
Aims: Serum creatinine and albuminuria are the core of most CKD prediction and progression risk models. Several biomarkers have been introduced to improve these results such as beta‐2‐microglobulin (B2M) and cystatin C (CysC). Nevertheless, few clinical comparisons of these biomarkers are available. We have compared serum B2M levels with albuminuria, CysC levels, and the CKD‐EPI GFR equations.Designs and Methods: A sample of 434 patients were studied: 234 males and 200 females, the mean age was 58.3 ± 15.0 years, and 33.4% have diabetes mellitus. In all patients, plasma B2M, CysC, creatinine, and urinary albumin excretion were analyzed. EGFR was calculated using CKD‐EPI equations for creatinine, CysC, and creatinine‐CysC. The risk of death and CKD progression was evaluated using ROC curves and Cox proportional hazards survivorship models.Results: For mortality, the highest area under the curve (AUC) was for CysC (0.775, 0.676–0.875). The lowest sensitivity was shown by eGFR (creatinine) (0.298, 0.195–0.401, p < 0.001), eGFR (CysC) (0.216, 0.118–0.314, p < 0.001), and eGFR (creatinine + CysS) (0.218, 0.124–0.312, p < 0.001). For progression to advanced CKD, the highest AUC was for CysC (0.908, 0.862–0.954). The lowest sensitivity was shown by eGFR (creatinine) (0.184, 0.106–0.261, p < 0.001), eGFR (CysC) (0.095, 0.048–0.14, p < 0.001), and eGFR (creatinine+ CysC) (0.087, 0.040–0.134, p < 0.001). CysC, after age, was the second‐best marker of life risk. Contrariwise, for CKD progression, CysC, and albuminuria were the best markers.Conclusions: The best biomarker of mortality and risk of progression to CKD was CysC. Albuminuria and B2M were the next best options to be used. The lowest sensitivity was shown by estimated eGFR.
- 23 December 2024
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 39 (2) , e25139
Open AccessComparative Prognostic Value of Glomerular Filtration Rate, Serum Cystatin C, Beta‐2‐Microglobulin and Albuminuria for Death and Chronic Kidney Disease Progression
Aims: Serum creatinine and albuminuria are the core of most CKD prediction and progression risk models. Several biomarkers have been introduced to improve these results such as beta‐2‐microglobulin (B2M) and cystatin C (CysC). Nevertheless, few clinical comparisons of these biomarkers are available. We have compared serum B2M levels with albuminuria, CysC levels, and the CKD‐EPI GFR equations.Designs and Methods: A sample of 434 patients were studied: 234 males and 200 females, the mean age was 58.3 ± 15.0 years, and 33.4% have diabetes mellitus. In all patients, plasma B2M, CysC, creatinine, and urinary albumin excretion were analyzed. EGFR was calculated using CKD‐EPI equations for creatinine, CysC, and creatinine‐CysC. The risk of death and CKD progression was evaluated using ROC curves and Cox proportional hazards survivorship models.Results: For mortality, the highest area under the curve (AUC) was for CysC (0.775, 0.676–0.875). The lowest sensitivity was shown by eGFR (creatinine) (0.298, 0.195–0.401, p < 0.001), eGFR (CysC) (0.216, 0.118–0.314, p < 0.001), and eGFR (creatinine + CysS) (0.218, 0.124–0.312, p < 0.001). For progression to advanced CKD, the highest AUC was for CysC (0.908, 0.862–0.954). The lowest sensitivity was shown by eGFR (creatinine) (0.184, 0.106–0.261, p < 0.001), eGFR (CysC) (0.095, 0.048–0.14, p < 0.001), and eGFR (creatinine+ CysC) (0.087, 0.040–0.134, p < 0.001). CysC, after age, was the second‐best marker of life risk. Contrariwise, for CKD progression, CysC, and albuminuria were the best markers.Conclusions: The best biomarker of mortality and risk of progression to CKD was CysC. Albuminuria and B2M were the next best options to be used. The lowest sensitivity was shown by estimated eGFR.
- Open Access
- 21 February 2024
- Published by Elsevier in Medicina Clinica
- Vol. 162 (11) , 511-515
Valor pronóstico de la elevación aislada de los niveles de cistatina C sin reducción del filtrado glomerular
- 21 February 2024
- Published by Elsevier in Medicina Clinica
- Vol. 162 (11) , 511-515
Open AccessValor pronóstico de la elevación aislada de los niveles de cistatina C sin reducción del filtrado glomerular
- Open Access
- 18 March 2021
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 20, 698-708
Plasma and urinary concentrations of arachidonic acid-derived eicosanoids are associated with diabetic kidney disease
Preclinical studies indicate that arachidonic acid (AA)-derived eicosanoids contribute to hyperglycemia-induced kidney injury. We aimed to determine whether plasma and/or urinary levels of dihydroxyeicosatrienoic (DHETs) and 20-hydroxyeicosatetraenoic (20-HETE) acids are associated with diabetic kidney disease (DKD). A total of 334 subjects (132 DKD patients and 202 non-diabetic individuals) were studied. Plasma levels of 11,12-DHET, 14,15-DHET and 20-HETE were measured by LC/MS/MS. Urinary 20-HETE concentrations were determined by immunoenzymatic assay. Subjects with normoalbuminuria had larger 20-HETE-to-creatinine urinary ratios (20-HETE/Cr) than those with micro and macroalbuminuria (p=0.012). Likewise, participants with eGFR>60 ml/min/1.73 m2 had higher plasma levels of 14,15-DHET (p=0.039) and 20-HETE/Cr ratios (p=0.007). Concentrations of 14,15-DHET, 11,12-DHET and 20-HETE/Cr were significantly lower in DKD patients. Median values for non-diabetic vs. DKD were, respectively, 493 (351.0-691.5) vs. 358 (260.5-522) ng/L, p=3e-5; 262 (183.5-356.0) vs. 202 (141.5-278.0) ng/L, p=1e-4 and 5.26 (1.68-11.65) vs. 2.53 (1.01-6.28) ng/mgCr, p=0.010. In addition, 20-HETE/Cr ratios were higher in patients with non-proteinuric DKD than in those with typical DKD (p=0.020). When only individuals with impaired filtration were considered, 14,15-DHET and 11,12-DHET levels were still higher in non-diabetic subjects (p=0.002 and p=0.006, respectively). Our results indicate that AA-derived eicosanoids may play a relevant role in DKD.
- 18 March 2021
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 20, 698-708
Open AccessPlasma and urinary concentrations of arachidonic acid-derived eicosanoids are associated with diabetic kidney disease
Preclinical studies indicate that arachidonic acid (AA)-derived eicosanoids contribute to hyperglycemia-induced kidney injury. We aimed to determine whether plasma and/or urinary levels of dihydroxyeicosatrienoic (DHETs) and 20-hydroxyeicosatetraenoic (20-HETE) acids are associated with diabetic kidney disease (DKD). A total of 334 subjects (132 DKD patients and 202 non-diabetic individuals) were studied. Plasma levels of 11,12-DHET, 14,15-DHET and 20-HETE were measured by LC/MS/MS. Urinary 20-HETE concentrations were determined by immunoenzymatic assay. Subjects with normoalbuminuria had larger 20-HETE-to-creatinine urinary ratios (20-HETE/Cr) than those with micro and macroalbuminuria (p=0.012). Likewise, participants with eGFR>60 ml/min/1.73 m2 had higher plasma levels of 14,15-DHET (p=0.039) and 20-HETE/Cr ratios (p=0.007). Concentrations of 14,15-DHET, 11,12-DHET and 20-HETE/Cr were significantly lower in DKD patients. Median values for non-diabetic vs. DKD were, respectively, 493 (351.0-691.5) vs. 358 (260.5-522) ng/L, p=3e-5; 262 (183.5-356.0) vs. 202 (141.5-278.0) ng/L, p=1e-4 and 5.26 (1.68-11.65) vs. 2.53 (1.01-6.28) ng/mgCr, p=0.010. In addition, 20-HETE/Cr ratios were higher in patients with non-proteinuric DKD than in those with typical DKD (p=0.020). When only individuals with impaired filtration were considered, 14,15-DHET and 11,12-DHET levels were still higher in non-diabetic subjects (p=0.002 and p=0.006, respectively). Our results indicate that AA-derived eicosanoids may play a relevant role in DKD.